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 Neointimal lesion development is a chronic inflammatory process that involves excessive cell proliferation and migration within the artery
wall. Progression through the mammalian cell cycle requires the sequential activation of holoenzymes composed of a catalytic cyclin-
dependent protein kinase (CDK) and a regulatory subunit named cyclin. Members of the family of CDK inhibitory proteins (CKIs) interact
with and inhibit the activity of CDK/cyclins. Cell migration occurs predominantly at the G1/S phase of the cell cycle, and both CDKs and
CKIs are among the molecular machines that coordinately regulate the cycling events that control cell proliferation and locomotion. The
purpose of this review is to discuss the role of CDK/cyclins and CKIs in the regulation of vascular cell proliferation and migration and in the
control of neointimal thickening. Pharmacological and gene therapy strategies targeting these cell cycle regulators for the treatment of
cardiovascular disease will also be discussed.
D 2004 European Society of Cardiology. Published by Elsevier B.V. All rights reserved.  June 3, 2016Keywords: Vascular cell proliferation; Migration; CDK1. Introduction
Atherosclerosis is a multifactorial process that involves
adaptative and innate immune mechanisms [1–4] (Fig. 1).
Endothelial cell (EC) dysfunction induced by atherogenic
stimuli is one of the earliest alterations at sites of predispo-
sition to atherosclerosis. The damaged endothelium pro-
motes the adhesion and transendothelial migration of
circulating leukocytes. Early fatty streaks contain mostly
highly proliferative macrophages that avidly uptake lip-
oproteins to become lipid-laden foam cells. Activated inti-
mal leukocytes produce a plethora of inflammatory
mediators that promote vascular smooth muscle cell
(VSMC) proliferation and migration towards the atheroscle-
rotic lesion, thus further contributing to atheroma growth
[1,2,5,6]. Excessive cell proliferation and migration are also
involved in the growth of vascular obstructive lesions during
restenosis post-angioplasty, transplant vasculopathy, and
graft atherosclerosis. Plaque rupture or erosion at advanced0008-6363/$ - see front matter D 2004 European Society of Cardiology. Publishe
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E-mail address: vandres@ibv.csic.es (V. Andre´s).disease stages can lead to acute occlusion due to thrombus
formation, resulting in myocardial infarction or stroke.
While several proliferation markers are expressed in
human neointimal lesions [7–16], the magnitude of prolif-
eration during human atherosclerosis and restenosis has
been controversial, with some studies reporting very low
proliferative rates [8,9,11,13,15] and others reporting abun-
dance of proliferation [10,17]. Factors that may contribute to
these differences include technical issues (e.g., differences
in tissue fixatives, antigen accessibility, analysis of different
proliferation markers), differences in the arteries being
analyzed (e.g., peripheral versus coronary and carotid arter-
ies, primary atheroma versus restenotic lesion), and variance
in lesion stage at the time of tissue harvesting. Indeed, cell
proliferation appeared more pronounced in restenotic versus
primary lesions [11,17,18], and primary VSMCs obtained
from human advanced primary stenosing displayed fewer
proliferation than cells from fresh restenosing lesions [19],
suggesting that cell proliferation is maximal at early stages
of neointimal thickening. Consistent with this interpretation,
atheroma size and cellular proliferation within the athero-
matous plaque of hyperlipidemic rabbits are inverselyd by Elsevier B.V. All rights reserved.
Fig. 1. Mechanisms involved in atherothrombosis. Based on the response-to-injury hypothesis proposed by Ross [1], the cartoon illustrates different stages of
atheroma progression, from a ‘‘healthy’’ artery wall (far left) to an advanced plaque (far right). Several atherogenic stimuli (i.e., hypercholesterolemia,
hypertension, diabetes, smoking) trigger the recruitment and activation of circulating leukocytes, which in turn promote the accumulation of SMCs within the
growing atheroma. Plaque rupture or erosion can lead to thrombus formation and acute ischemic events.
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 correlated [20–22], and experimental angioplasty is char-
acterized by the reestablishment of the quiescent phenotype
after the initial proliferative burst [5,23].
The mammalian cell cycle is controlled by holoenzymes
composed of a catalytic cyclin-dependent protein kinase
(CDK) and a regulatory cyclin [24]. Different CDK/cyclin
complexes are orderly activated at specific phases of the
cell cycle (Fig. 2). CDK/cyclin-dependent hyperphosphor-
ylation of the retinoblastoma protein (pRb) and the related
pocket proteins p107 and p130 from mid G1 to mitosis
contributes to the transactivation of genes with functional
E2F-binding sites, including growth and cell-cycle regula-
tors (i.e., c-myc, pRb, cdc2, cyclin E, cyclin A), and genes
encoding proteins required for nucleotide and DNA bio-
synthesis (i.e., DNA polymerase a, histone H2A, prolifer-
ating cell nuclear antigen, thymidine kinase) [25]. The
identities of substrates of the yeast CDK1 (CDC2) have
revealed that this enzyme employs a global regulatory
strategy involving phosphorylation of other regulatory
molecules as well as phosphorylation of the molecular
machines that drive cell-cycle events [26].Cyclin availability and phospo/dephosphorylation of
CDKs and cyclins regulate CDK/cyclin activity. CDK
activity is attenuated by the interaction with CDK inhibitory
proteins (CKIs) of the Cip/Kip (for CDK interacting protein/
Kinase inhibitory protein) and Ink4 (for inhibitor of CDK4)
families [24] (Fig. 2). Cip/Kip proteins (p21Cip1, p27Kip1,
p57Kip2) bind to and inhibit a wide spectrum of CDK/cyclin
holoenzymes, while Ink4 proteins (p16Ink4a, p15Ink4b,
p18Ink4c, p19Ink4d) are specific for cyclin D-associated
CDKs. Mitogenic and antimitogenic stimuli affect the rates
of CKI synthesis and degradation, as well as their redistri-
bution among different CDK/cyclin heterodimers.2. Control of vascular cell proliferation and neointimal
lesion growth by CDKs and CKIs
VSMC proliferation in the balloon-injured rat carotid
artery is associated with a temporally and spatially coordi-
nated expression and activation of CDKs and cyclins
[16,27,28]. CDKs and cyclins are also expressed in human
Fig. 2. Cell cycle control in mammalian cells. Activation of specific CDK/cyclin complexes drives progression through the cell cycle (CDK1=CDC2). CKIs
interact with and inactivate CDK/cyclin holoenzymes.
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 VSMCs within atherosclerotic and restenotic tissue [10,16,
29], suggesting that assembly of functional CDK/cyclin
holoenzymes in the injured arterial wall is a hallmark of
vascular proliferative disease.
Numerous studies have implicated p27Kip1 and p21Cip1 in
the control of vascular cell proliferation in vitro and neo-
intimal thickening in vivo. For example, interleukin-1h-
induced p27Kip1 and p21Cip1 downregulation may stimulate
CDKs and promote neointimal VSMC proliferation [30]. In
contrast, salicylate-dependent inhibition of PDGF-induced
VSMC growth correlated with p27Kip1 and p21Cip1 accumu-
lation [31]. Likewise, beraprost sodium-dependent VSMC
growth arrest and reduction of intimal thickening in the
balloon-injured dog coronary artery correlated with high
p27Kip1 expression [32], and p21Cip1 induction was associ-
ated with tranilast-dependent inhibition of CDK2 and CDK4
activities, VSMC growth arrest in vitro and reduced intimal
hyperplasia in the rat balloon-injured carotid artery [33].
p27Kip1 and p21Cip1 upregulation may contribute to VSMC
growth arrest induced by non-steroidal anti-inflammatory
drugs [34], nitric oxide donors [35] and gene transfer of
endothelial nitric oxide synthase [36]. Simvastatin-depen-
dent inhibition of CDK2 activity and VSMC proliferation
correlates with prevention of Rho GTPase-induced down-
regulation of p27Kip1 without changes in p21Cip1, p16Ink4a,
or p53 levels [37]. p27Kip1 may also mediate protein kinase
Cy-mediated S-phase arrest in capillary ECs [38], and CDK2
inhibition and growth arrest in contact-inhibited ECs [39]. In
vitro exposure of VSMCs to carbon monoxide (CO) tran-
siently increases p21Cip1 expression and induces growth
arrest, and treatment of rats with CO suppresses arterioscle-rotic lesions associated with chronic graft rejection and with
balloon injury [40]. However, although p21Cip1 was essential
for CO-dependent VSMC growth arrest in vitro, the thera-
peutic effect of CO in a mouse model of mechanical arterial
injury was not impaired in p21Cip1-null mice [40].
Hemodynamic forces appear to play an important role in
atheroma development [1,2]. EC growth arrest induced by
steady laminar stress correlated with p21Cip1 upregulation
without changes in p27Kip1 protein levels [41]. Mattiussi et
al. have shown that p21Cip1 gene transfer protects ECs from
apoptosis induced by laminar shear stress in vitro, and
significantly reduced in vivo apoptosis in ECs of ischemic
hindlimbs [42]. On the other hand, stretch-mediated inacti-
vation of forkhead transcription factors and p27Kip1 down-
regulation in VSMCs was accompanied by activation of
CDK2, pRb hyperphosphorylation and proliferation, dem-
onstrating that the earliest cell cycle events in VSMCs can
occur in a solely mechanosensitive fashion [43]. RhoA-
dependent p27Kip1 downregulation, mediated in part via
phosphatidylinositol-3-kinase, induces VSMC proliferation
and may contribute to the enhanced vascular responsiveness
associated to hypertension [44].
p21Cip1 and p27Kip1 accumulation at late time points after
balloon angioplasty in rat and porcine arteries may limit
neointimal hyperplasia after the initial proliferative wave
[14,45,46]. Transluminal injury in the murine femoral artery
induces a rapid apoptotic response and p27Kip1 downregu-
lation in medial VSMCs followed by a gradual increase in
cell proliferation that peaked at 2 weeks in both the media
and neointima and decreased thereafter coinciding with
p27Kip1 upregulation [47]. The following observations sug-
Table 1
Pharmacological CDK inhibitors that limit neointimal hyperplasia in the rat
carotid artery model of balloon angioplasty
Agent IC50 for CDKs Dose and route of
administration
Ref.
CVT-313 CDK1 (CDC2)
= 4 AM
1.25 mg/kg,
brief intraluminal
[66]
CDK2= 0.5 AM exposure immediately
CDK4= 215 AM after angioplasty
Flavopiridol CDK1 (CDC2)
= 0.5 AM
5 mg/kg/day, oral [67–69,142]
CDK2= 0.1 AM
CDK4= 0.065 AM
CDK6= 0.06 AM
CDK7= 0.11-0.3 AM
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 gest a role for CKIs as regulators of human neointimal
hyperplasia: (a) reduced p27Kip1 expression in primary
atherosclerotic and restenotic lesions compared with aorta,
internal mammary artery, and carotid artery thrombendarter-
ectomy specimens [48]; (b) p21Cip1 upregulation in reste-
nosis compared with primary lesions and other vascular
regions [48]; (c) more frequent p27Kip1 and p21Cip1 expres-
sion within regions of coronary atheromas not undergoing
proliferation [14]; (d) concordant expression of TGF-h
receptors in virtually all cells positive for p27Kip1 within
atherosclerotic plaques, suggesting that the anti-mitogenic
action of TGF-h1 in these lesions may be mediated by
p27Kip1 [29]; and (e) p53 and p21Cip1 coexpression in
carotid atheromatous plaque cells that revealed lack of
proliferation markers, suggesting that p21Cip1 induction
may occur via p53-dependent transcriptional activation [49].
We have established a causal link between decreased
p27Kip1 protein expression and atherogenesis in hypercho-
lesterolemic apolipoprotein E (apoE)-null mice by demon-
strating that whole-body genetic inactivation of p27Kip1
increases arterial VSMC and macrophage proliferation and
accelerates atherosclerosis [50]. We have also shown that
selective inactivation of p27Kip1 in hematopoietic progenitor
cells increases neointimal macrophage proliferation and is
sufficient to accelerate atherosclerosis in fat-fed apoE-defi-
cient mice [51], consistent with previous studies demonstrat-
ing enhanced haematopoietic progenitor cell proliferation
upon p27Kip1 inactivation [52], and implicating p27Kip1 as a
critical macrophage growth suppressor [53,54]. Because
macrophages were the most abundant neointimal cells in
our study [51], it seems reasonable to suggest that macro-
phage p27Kip1 safeguards against the inflammatory/prolifer-
ative response induced by dietary cholesterol in apoE-null
mice. Regarding the consequences of CKI inactivation on
neointimal thickening induced by vascular mechanical inju-
ry, a threefold increase in lesion size was observed in
p21Cip1-null versus wild-type mice [40], but p27Kip1 genetic
ablation did not affect lesion size [55]. Redundant roles
between p21Cip1 and p27Kip1, or a compensatory increase in
p21Cip1 expression (or other CKIs) might account for the
lack of phenotype of p27Kip1-null mice in the setting of
mechanical arterial injury.
Regional differences in the proliferative response of
VSMCs have been established, both when comparing cells
from different compartments of the same vessel and cells
isolated from vessels from different vascular beds [56–62],
and several studies suggest that distinct CKI regulation may
contribute to establishing these regional dissimilarities.
Sustained p27Kip1 expression in spite of growth stimuli
may contribute to the resistance to growth of human
VSMCs isolated from internal mammary artery compared
with saphenous vein VSMCs, and to the longer patency of
arterial versus venous grafts [61]. Likewise, distinct p15Ink4b
and p27Kip1 expression correlated with different prolifera-
tive potential of intimal and medial VSMCs stimulated with
basic fibroblast growth factor [62]. We have recently shownintrinsic differences in the regulation of the mitogen-acti-
vated protein kinase (MAPK)/extracellular signal-regulated
kinase (ERK) pathway and p27Kip1 that may contribute to
creating regional variability in the proliferative and migra-
tory capacity of VSMCs from vascular beds with different
atherogenicity [63]. Developmental differences in ERK
activity also correlate with distinct proliferative and migra-
tory capacity of VSMCs derived from the aortae of newborn
versus adult rats [64].
Using primary cultures of human VSMCs, mitogen-
induced proliferation was higher in cells derived from
normal media (M-VSMCs), intermediate in cells from in-
stent stenosis sites (ISS-VSMC), and lower in cells from
primary atherosclerotic plaques (P-VSMC) [65]. Compared
with M-VSMCs, P-VSMCs expressed high levels of
p16Ink4a and p21Cip1, reduced p27Kip1 and cyclin E expres-
sion, and diminished pRb phosphorylation. ISS-VSMCs
also displayed high levels of p21Cip1 and reduced p27Kip1
expression compared with M-VSMCs, although cyclin A
and E expression was highest in ISS-VSMCs. Based on
these findings, the authors have suggested that ISS-VSMCs
derive from P-VSMCs driven to proliferate through cyclin E
overexpression [65].3. CDK inhibitory approaches to reduce neointimal
thickening
Pharmacological (Table 1) and gene therapy (Table 2)
CDK inhibitory strategies can limit experimental neointimal
lesion growth. The relative inhibitory potency of the purine
derivative CVT-313 varies from very high for CDK2,
moderate for CDK1, and very low for CDK4 [66]. Flavo-
piridol (L86-8275) is a more potent CDK inhibitor that
displays higher specificity towards CDK4 than towards
CDK1 and CDK2 [67,68]. Flavopiridol- and CVT-313-
dependent VSMC growth arrest correlates with decreased
pRb hyperphosphorylation [66,69]. In the rat carotid model
of balloon angioplasty, a brief intraluminal exposure to
CVT-313 [66] or oral administration of flavopiridol for 5
Table 2
CDK/cyclin inhibitory gene therapy strategies that limited experimental neointimal thickening
Strategy Targeted gene Strategy Model Ref.
Antisense-mediated CDK/ CDK2 ODN Balloon angioplasty (rat) [27,70]
cyclin inactivation CDK2 ODN Graft atherosclerosis (mouse) [75]
CDC2 ODN Balloon angioplasty (rat) [27,71,72]
cyclin B1 ODN Balloon angioplasty (rat) [72]
CDC2/PCNA ODN Graft atherosclerosis (rabbit, rat) [74]
cyclin G1 Retrovirus Balloon angioplasty (rat) [73]
CKI overexpression p21Cip1 Adenovirus Balloon angioplasty (rat, mouse, pig) [77–79,82]
p21Cip1 Plasmid Graft atherosclerosis (rabbit) [83]
p27Kip1 Adenovirus Balloon angioplasty (rat, pig) [44,80]
p57Kip2 Adenovirus Balloon angioplasty (rabbit) [81]
p27Kip1-p16Ink4a chimera Adenovirus Balloon angioplasty (rabbit, pig) [85,86]
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 days beginning at the day of injury [69] reduced neointima
formation by 80% and 39%, respectively.
Antisense oligodeoxynucleotide (ODN) against CDK2
[27,70], CDC2 [27,71,72], and cyclin B1 [72] reduced
neointimal thickening after balloon angioplasty. Likewise,
cyclin G1 inactivation by retrovirus-mediated antisense
gene transfer inhibited VSMC proliferation and neointima
formation after balloon angioplasty [73], and antisense
ODN to CDC2/PCNA [74] and CDK2 [75] attenuated graft
atherosclerosis. Additional approaches based on the inacti-
vation of positive cell cycle regulators that do not directly
target CDK/cyclin activity (i.e., E2F, c-myc, etc.) have been
reviewed elsewhere [6,76].
Gene transfer of p21Cip1 [77–79], p27Kip1 [45,80], and
p57Kip2 [81] reduced neointima formation after angioplasty
in normocholesterolemic animals. Likewise, p21Cip1 over-
expression attenuated neointimal thickening after balloon
injury in hypercholesterolemic mice [82] and following vein
grafting [83]. Lamphere et al. [84] generated chimeric
p16Ink4a and p27Kip1 molecules, which were of comparable
potency to the parental p27Kip1 in inhibiting the activities of
several CDKs in vitro. Among these chimeras, W9 was the
most potent growth suppressor of human coronary artery
VSMCs and ECs when compared to the parental p16Ink4a
and p27Kip1, p27Kip1 derivatives, or several alternative
p27Kip1–p16Ink4a chimeras. Importantly, W9 inhibited neo-
intimal hyperplasia and artery occlusion when delivered to
balloon-injured porcine arteries [85], and was more effective
than the p27Kip1 and p16Ink4a parental genes in inhibiting
neointimal thickening after balloon angioplasty in choles-
terol-fed rabbits [86]. Further approaches based on the
overexpression of growth suppressor that do not directly
target CDK/cyclin activity (i.e., pRb, p53, Gax, etc.) are
reviewed elsewhere [6,76].4. Control of cell migration by CDKs and CKIs
Several cytostatic agents (e.g., quercetin, mimosine,
suramin, rapamycin, and troglitazone) can reduce the
migratory potential of VSMCs and tumour cells [87–92]. Likewise, 17h-estradiol and the transcription factors
p53, AP-1 and c-myc regulate in a coordinated manner
the proliferative and migratory potential of ECs and
VSMCs [93–96]. NBT-II rat bladder carcinoma cells
synchronized in G1 migrated simultaneously upon FGF-
1 stimulation, and cells arrested in G2/M did not respond
to stimulation by this mitogen [97]. Moreover, maximal
migration of PDGF-BB-stimulated VSMCs occurred in
late G1 [98]. These studies indicate that the position in
the cell cycle is a key determinant of a cell’s competence
for migration. Consistent with this notion, many genes
involved in cell motility (including cytoskeletal reorgani-
zation genes and extracellular matrix remodelling genes)
exhibit cell cycle-dependent regulation in human fibro-
blasts [99]. Moreover, disruption of the actin cytoskeleton
in murine Swiss 3T3 fibroblasts leads to inhibition of
mitogen-induced cyclin E expression, CDK2 phosphory-
lation, and nuclear accumulation of the pRb-related p107
protein, further establishing a link between the cell cycle
and locomotion machineries [100].
Overexpression of p27Kip1, p16INK4a and p21Cip1 inhibits
cell spreading and migration in human umbilical vein ECs,
CS-1 h3 melanoma cells, VSMCs and NIH-3T3 fibroblasts
[63,101–103]. Moreover, p27Kip1-null VSMCs were more
resistant than wild-type cells to the antimigratory properties
of rapamycin [104]. Regarding the role of CDKs on cell
locomotion, CDK6 localized to the ruffling edge of spread-
ing cells and suppressed p16INK4a-mediated inhibition of
cell spreading [102]. By analyzing chimeric mice obtained
by injection of CDK5-null embryonic stem cells into host
blastocysts, Ohshima et al. [105] suggested that CDK5 is
required for specific components of neuronal migration that
are differentially required by different neuronal cell types
and by even a single neuronal cell type at different devel-
opmental stages. Moreover, it has been suggested that
CDK5 may be a general regulator of cytoskeletal organiza-
tion and cell adhesion in both neuronal and non-neuronal
cells [106]. Mechanisms that may contribute to CDK5-
dependent control of cell migration include the regulation
of cytoskeletal dynamics by p39/CDK5 complexes [107],
and CDK5 phosphorylation of serine 732 of focal adhesion
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 kinase (FAK) through regulation of a microtubule fork
important for nuclear translocation [108,109].
In addition to their well-established role in regulating cell
shape and locomotion, specific components of the extracel-
lular matrix and integrins play an important role in the
control of vascular and nonvascular cell proliferation
[110,111]. Significant changes in matrix collagen content
occur during neointimal lesion development [112–114].
Because polymerized collagen may mimic the scenario of a
normal artery composed of quiescent VSMCs, and monomer
collagen might resemble the extracellular matrix surrounding
proliferating neointimal VSMCs, Koyama et al. [115] studied
the growth properties of VSMCs cultured on monomer
collagen fibers and on polymerized collagen. Mitogen-stim-
ulated VSMCs grown on monomer collagen disclosed high
proliferative activity, but underwent G1 arrest when seeded
on polymerized collagen. This inhibitory effect of polymer-
ized collagen appeared to be mediated by a2 integrins, and
correlated with suppression of p70S6K and p27Kip1 upregu-
lation (and to a lesser extent p21Cip1). Interestingly, the
quiescent phenotype of nonadherent NRK fibroblasts corre-
lated with an increased association of p27Kip1 and p21Cip1 to
cyclin E-containing holoenzymes [116], and E-cadherin-
dependent inhibition of nonadherent EMT/6 mouse mam-
mary carcinoma cells involves upregulation of p27Kip1 [117].
Moreover, evidence has been presented suggesting that
tension-dependent changes in cell shape and cytoskeletal
structure play an important role in the control of EC prolif-
eration via modulation of cell cycle regulatory factors,Fig. 3. Coordinate control of cell proliferation and migration. In the presen
hyperphosphorylation of pRb, release of E2F and high proliferative and migratory
the accumulation of hypophosphorylated pRb, sequestration of E2F and low pro
inhibitory strategies that inhibited experimental neointimal thickening (see Tablesincluding p27Kip1 [118]. It is also noteworthy that antisense
ODN-mediated p21Cip1 inactivation in VSMCs attenuated
the production and secretion of the ECM proteins fibronectin
and laminin [119]. Further in vivo studies are required to
elucidate possible links between various CKIs, the mainte-
nance of cell shape, and dynamic modulation of cell–
substrate interactions within the artery wall.
In view of the molecular connections between cell
proliferation and migration, we have investigated whether
the dual function of p27Kip1 as a cell-cycle and migration
inhibitor is achieved via common or independent molecu-
lar pathways [120]. Physiologically high level of p27Kip1
expression inhibited CDK activity and attenuated both
proliferation and migration in VSMC and fibroblast cul-
tures, and mutations that rendered p27Kip1 unable to
abrogate CDK activity also prevented p27Kip1-induced
growth arrest and migration blockade. Moreover, a consti-
tutively active mutant of pRb insensitive to CDK-depen-
dent hyperphosphorylation inhibited both cell proliferation
and migration, and pRb inactivation by forced expression
of the adenoviral oncogene E1A correlated with high
proliferative and migratory activity. Thus, cellular prolifer-
ation and migration appear to be coordinately regulated by
the p27Kip1/CDK/pRb/E2F pathway (Fig. 3). Consistent
with this notion, E2F-1-null keratinocytes exhibited delay
in transit through both G1 and S phases of the cell cycle
and substantially impaired migration [121]. Future studies
are necessary to identify E2F-regulated genes implicated in
cell locomotion.ce of low level of CKIs, active CDK/cyclin holoenzymes trigger the
activity. In contrast, CDK/cyclin inactivation by high level of CKIs leads to
liferative and migratory activity. The schematic shows several CDK/cyclin
1 and 2).
 June 3, 2016
V. Andre´s / Cardiovascular Research 63 (2004) 11–21 17Regarding the signal transduction pathways that contrib-
ute to coordinate regulation of cell growth and locomotion,
higher proliferative and migratory capacities of phenotypi-
cally distinct VSMC subtypes (aorta versus femoral artery
VSMC, or aorta VSMCs from newborn versus old rats)
correlate with greater ERK activity [63,64]. We have shown
that retrovirus-mediated constitutive activation of ERK
diminished p27Kip1 expression and markedly augmented
PDGF-BB-mediated VSMC proliferation and migration,
and pharmacological ERK inhibition increased p27Kip1
expression and attenuated PDGF-BB-induced VSMC pro-
liferation and migration [63]. Likewise, Zhan et al. [122]
found that adenovirus-mediated overexpression of dominant
negative mutated variants of ERK, p38 and c-Jun N terminal
kinase (JNK) inhibited PDGF-BB-stimulated VSMC prolif-
eration and migration. These authors also showed that ERK
and JNK inactivation suppressed PDGF-BB-induced down-
regulation of p27Kip1, whereas p38 blockade decreased
PDGF-BB-dependent upregulation of p21Cip1.by guest on June 3, 2016
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 5. Concluding remarks
Excessive cell proliferation and migration contribute to
neointimal thickening, and CDKs, cyclins and CKIs are key
regulators of these processes in vitro. Moreover, changes in
the expression and/or activity of these cell cycle regulators
have been documented in several animal models of vascular
proliferative disease and in human atherosclerotic and rest-
enotic tissue, and CDK/cyclin inhibition limited experimen-
tal neointimal thickening. Regarding the potential
therapeutic application of these strategies to prevent human
vascular obstructive disease, several issues need to be
considered in the risk–benefit analysis of this approach.
For instance, the prevention of cell proliferation and migra-
tion can be accompanied by VSMC an EC apoptosis leading
to increased dysfunction of the vessel and possible predis-
position to rupture of advanced atherosclerotic plaques. Of
note in this regard, the anti-proliferative effect of the CDK
inhibitor roscovitine is more potent in cells derived from
human in-stent stenosis sites than in medial VSMCs [65].
Thus, studies to assess the therapeutic efficacy of roscovitine
to limit in-stent stenosis are warranted. Given the emerging
evidence suggesting the contribution of progenitor cells to
vascular lesion formation (reviewed in Refs. [123,124]),
potential effects of cell cycle inhibition on the behaviour of
circulating progenitor cells warrant investigation. For exam-
ple, it appears important to ascertain whether cell cycle
inhibiting strategies can effectively prevent the accumula-
tion, proliferation and differentiation of progenitor cells to
VSMC, thereby preventing increased neointimal formation,
or whether such strategies will rather be detrimental by
inhibiting endothelial progenitor cell adhesion, proliferation,
neoangiogenesis and restoration of damaged tissue.
Because patients frequently exhibit advanced atheroscle-
rotic plaques when first diagnosed and cell proliferation islikely to peak at the early stages of human atheroma
development, the potential benefit of antiproliferative strat-
egies for the treatment of human atherosclerosis is uncertain.
Indeed, the antiproliferative approaches used so far in the
setting of vascular obstructive disease have focused on
restenosis and graft atherosclerosis, during which neointimal
hyperplasia is spatially localized and develops over a short
period of time (typically 2–12 months). Synthetic CDK
inhibitors (CVT-313, flavopiridol), antisense strategies tar-
geting CDK/cyclins, and CKI overexpression reduced neo-
intimal hyperplasia after experimental graft atherosclerosis
and angioplasty, although the therapeutic efficacy of these
CDK inhibitory strategies has not been yet assessed in
clinic. In this regard, it is notable that several promising
in vitro and animal study cell cycle inhibition approaches
have not been successful to date in clinical trials. Factors
that may contribute to these differences include inadequate
study designs (i.e., incorrect doses, duration of treatment, or
mode of application), inter-species heterogeneity, and phe-
notypic variability of VSMCs in different vascular beds.
Despite all the above drawbacks and potential detrimental
side effects, antiproliferative approaches have shown prom-
ising results in preventing human neointimal thickening. The
bacterial macrolide rapamycin (sirolimus, rapamune) is the
pharmacological agent with which most experience has been
gathered so far for the prevention of in-stent restenosis.
Rapamycin is a potent immunosuppressant that strongly
inhibits VSMC proliferation and migration via both
p27Kip1-dependent and p27Kip1-independent mechanisms
(reviewed in Refs. [125]). Rapamycin potently inhibited
neointimal thickening in animal models of angioplasty, graft
atherosclerosis, and diet-induced atherosclerosis [55,126–
134], and recent clinical trials using rapamycin-impregnated
stents have shown promising results for the prevention of
neointimal proliferation, restenosis, and associated clinical
events in patients undergoing coronary angioplasty [135–
137]. Activation of E2F is triggered by CDK-dependent
phosphorylation of pRb and related pocket proteins, there-
fore E2F inhibition may be a common mechanism by which
different CDK/cyclin inhibitory strategies reduce neointimal
thickening. E2F inactivation via transfection of synthetic
ODN containing an E2F consensus binding site reduced
hyperplasia after experimental balloon angioplasty and vein
grafting [138,139], and application of this E2F ‘decoy’
strategy is safe and can achieve sequence-specific inhibition
of cell-cycle gene expression and DNA replication in
patients receiving ortocoronary bypass [140,141]. Despite
these encouraging results, significant effort in basic research
is warranted to identify additional target genes and strategies
for the treatment of cardiovascular disease.Acknowledgements
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